NASDAQ: CELC - Celcuity Inc.

Rentabilität für sechs Monate: -37.42%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Celcuity Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Celcuity Inc.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

weitere details
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2017-09-20
ISIN US15102K1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.celcuity.com
Цена ао 10.44
Preisänderung pro Tag: +2.05% (9.75)
Preisänderung pro Woche: +21.19% (8.21)
Preisänderung pro Monat: -0.7976% (10.03)
Preisänderung über 3 Monate: -5.51% (10.53)
Preisänderung über sechs Monate: -37.42% (15.9)
Preisänderung pro Jahr: -45% (18.09)
Preisänderung über 3 Jahre: +32.31% (7.52)
Preisänderung über 5 Jahre: +57.94% (6.3)
Preisänderung seit Jahresbeginn: -17.08% (12)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 2.54 6
P/E 0 0
EV/EBITDA -5.47 0
Gesamt: 3

Effizienz

Name Bedeutung Grad
ROA, % -33.35 0
ROE, % -45.63 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.5632 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 687.97 10
Rentabilität EPS, % 292.34 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Morgan Stanley 2195179 7.21
Soleus Capital Management, L.P. 2179481 7.16
VR Adviser, LLC 1885538 6.19
COMMODORE CAPITAL LP 1754704 5.76
Perceptive Advisors LLC 1481300 4.86
NEA Management Company, LLC 1250001 4.1
Blackrock Inc. 1050391 3.45
Vanguard Group Inc 820776 2.7
CapTrust Financial Advisors 544835 1.79
Baker Brothers Advisors, LLC 535478 1.76

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Jacob Forward ETF 0.85997 43.03 0.15284
iShares Morningstar Small-Cap Growth ETF 0.00891 596.94 0.72598
iShares Morningstar Small-Cap ETF 0.00435 391.25 1.60498
0.29343.740.83



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Brian F. Sullivan Co-Founder, Chairman & CEO 478.12k 1962 (63 Jahr)
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, VP, Secretary & Director 389.55k 1962 (63 Jahr)
Ms. Vicky Hahne Chief Financial Officer 281.59k 1966 (59 Jahre)
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of R&D N/A 1955 (70 Jahre)
Ms. Sheri Smith Acting Head of Clinical Operations N/A
Mr. Igor Gorbatchevsky M.D. Chief Medical Officer N/A
Mr. Eldon C. Mayer III, M.B.A. Chief Commercial Officer N/A 1961 (64 Jahr)
Dr. Charlotte Moser M.B.A., M.D., M.Sc., Ph.D. Senior Vice President of Clinical Development

Adresse: United States, Minneapolis. MN, 16305–36th Avenue North - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.celcuity.com